7th ENEA VIRTUAL Workshop — Cushing's Disease

Programme

7th ENEA Virtual Workshop, Dubrovnik, Croatia, 10-11 December 2021

Friday, 10 December 2021
09:20-09:30	Workshop opening I. Shimon (Israel), D. Kastelan (Croatia)
09:30-10:45	Chair: M. Toth (Hungary), K. Alexandraki (Greece)
	Session 1: Diagnosis and subtyping of Cushing’s syndrome Clinical presentation and etiology of Cushing’s syndrome– data from ERCUSYN – E. Valassi (Spain) Diagnostic workup for Cushing’s syndrome – S. Tsagarakis (Greece) Novel imaging modalities in Cushing’s disease – M. Gurnell (UK)
10:45-10:55	Coffee break
10:55-11:45	Chair: N. Biermasz (Netherlands), R. Luque (Spain)
	Session 2: Basic science/Molecular aspects of CS Genetics of Cushing’s disease – M. Theodoropoulou (Germany) Genetic and molecular causes of adrenocortical hyperplasia – G. Assié (France)
11:45-12:25	Chair: I. Shimon (Israel), A. Isidori (Italy)
	DEBATE 1: Should IPSS be performed in patients with ACTH dependant CS? PRO and CON – J. Newell-Price (UK) / A. Tabarin (France)
12:25-12:35	Coffee break
12:35-14:15	Chair: Lj. Marina (Serbia), P. Petrossians (Belgium)
	Session 3: Comorbidities in patients with glucocorticoid excess Metabolic side effects of glucocorticoids – M. Korbonits (UK) Long-term consequences of cortisol excess on the brain – A. Pereira (Netherlands) Cardiovascular complications of Cushing’s syndrome – R. Clayton (UK) Bone complications of Cushing’s syndrome – N. Gittoes (UK) Coagulation abnormalities in Cushing’s syndrome – R. Feelders (Netherlands)
14:15-15:00	Lunch break
15:00-16:00	Chair: C.N. Olarescu (Norway), L.P. Rivas (Germany)
	ENEA Young Investigator Symposium USP8 mutations in corticotroph tumors: clinical-biochemical features and pharmacological implications – A. Albani (Germany) Molecular mechanisms involved in somatostatin receptors regulation in corticotroph tumors: the role of cytoskeleton and USP8 mutations – E. Peverelli (Italy) Mapping the transcriptomic and epigenetic landscapes of corticotrophs and precursors at single nucleus resolution – Frederique Ruf-Zamojski (USA)
16:00-16:45	Chair: I. Shimon (Israel), M.C. Zatelli (Italy)
	*Rolf Gaillard Prize Lecture* Fate of corticotroph cells from development to tumorigenesis – J. Drouin (Canada)
16:45-18:15	Industry symposium – Recordati Rare Diseases Welcome and introduction – M. Reincke (Germany) The treatment landscape: How far have we come? – M. Fleseriu (USA) What’s what in the management of Cushing’s syndrome? A multidisciplinary discussion – Presenter: R. Feelders (Netherlands) / Panel: All faculty How should we approach dose titration? A guided discussion – Presenter: M. Reincke (Germany) / Panel: M. Fleseriu (USA) & R. Feelders (Netherlands) Summary – M. Reincke (Germany) Live Q&A and close – Moderator: M. Reincke (Germany) / Panel: All faculty

Saturday, 11 December 2021
08:30-10:10	Chair: N. Karavitaki (UK), T. Kocjan (Slovenia)
08:30-08:55	Meet-the-expert: Pitfalls in the testing and diagnosis of Cushing’s syndrome – P. Trainer (UK)
08:55-09:20	Meet-the-expert: Pituitary vs ectopic ACTH secretion – diagnostic challenges – A.Grossman (UK)
09:20-09:45	Meet-the-expert: Challenges in neuroimaging of Cushing’s disease – J.F. Bonneville (Belgium)
09:45-10:10	Joint discussion following meet-the-expert sessions – P. Trainer (UK), A.Grossman (UK), J.F. Bonneville (Belgium)
10:10-11:25	Chair: G. Stalla (Germany), M. Solak (Croatia)
	Session 4: Treatment modalities in Cushing’s disease Surgery and perioperative management of patients with Cushing’s disease – J. Honegger (Germany) Medical management of Cushing’s disease – when and how? – F. Castinetti (France) Role of radiosurgery in treatment of Cushing’s disease – M. Losa (Italy)
11:25-11:35	Coffee break
11:35-12:15	Chair: M. Pfeifer (Slovenia), M.C. Zatelli (Italy)
	DEBATE 2: Bilateral adrenalectomy versus medical therapy for treatment of Cushing’s disease after unsuccessful pituitary surgery(ies) – A.Grossman (UK) / M. Gurnell (UK)
12:15-13:15	Chair: G. Trivellin (Italy), K. Zibar Tomsic (Croatia)
	*ENEA Young Investigator Oral Presentations* Studies on glucocorticoid receptor regulated genes as biomarkers of glucocorticoid bioavailability – J. Simon (Germany) Characterization of adrenal miRNA based dysregulations in Cushing’s syndrome – S. Vetrivel (Germany) Integrative clinical, biochemical, and molecular analysis for predicting evolution and curation in patients with Cushing’s disease – A. C. Fuentes-Fayos (Spain) Determination of Cushing’s syndrome chronotype with the Munich chronotype questionnaire and actigraphy – M. Mazari (Germany) Brown fat somatostatin receptor expression but not FDG activity is alerted in patients with ACTH-dependent Cushing’s syndrome – S. N. Sendur (Turkey)
13:15-14:05	Chair: A Beckers (Belgium), I. Kraljevic (Croatia)
	Session 5: Treatment challenges Aggressive corticotroph tumors – G. Raverot (France) Diagnosis and management of Cushing’s syndrome in pregnancy – N. Karavitaki (UK)
14:05-15:00	Lunch break
15:00-16:15	Chair: D. Miljic (Serbia), M. Gahete (Spain)
	Session 6: Long term consequences of CS Long term morbidity and mortality in patients with Cushing’s syndrome – M.Reincke (Germany) Long term follow-up and predictors of recurrence of Cushing’s disease – J. Bertherat (France) Recovery of HPA axis after surgery for Cushing’s syndrome – T. Dusek (Croatia)
16:15-17:45	Industry symposium – HRA Pharma Rare Diseases Welcome and introduction – Open symposium, review objectives, introduce faculty – J. Newell-Price (UK) Maintaining the biological rhythm: Why is it essential? – E. Valassi (Spain) Real-world cadence: Exploring the circadian rhythm in Cushing’s syndrome – F. Ceccato (Italy) Normalising cortisol levels: Findings from the PROMPT study – M. Reincke (Germany) Q&A and discussion – All faculty, led by J. Newell-Price (UK)

17:45–18:00

Best Poster Award and closing of the Workshop I. Shimon (Israel), D. Kastelan (Croatia), G. Raverot (France)